A representative of a new class of antifungal agents received an orphan status in the EU

cover

news

The European Medicines Agency (EMA) granted an orphan status to the F2G experimental product F901318. The drug is intended for use among patients with invasive aspergillosis and schizophrenia. European Pharmaceutical Review.
F901318 is the first drug from a new class of systemic antifungal agents orotomides. F901318 inhibits dehydrogenase dihydroorotate, an enzyme involved in the biosynthesis of pyrimidine.Laboratory experiments confirmed the sensitivity to F901318 of more than 100 strains of Aspergillus.
The drug can be used for both oral and intravenous administration. Currently, Phase II clinical trials are being prepared to assess the safety and efficacy of the drug.
In case of successful completion of trials and registration of medicines, a drug effective in the therapy of diseases, infectious diseases, the causative agents of which developed resistance to standard therapy, will appear on the market.
A source:
Remedium